MagnaPharm SK
Pharmaceutical import, local distribution and support services for manufacturers and customers in Slovakia
Highlights
- ProfitableFY2025 net profit €192k · RÚZ
- GrowingRevenue +902% YoY (FY2025) · RÚZ
- New on EvolcAdded 2026-11-01
Recent signals
What changed at MagnaPharm SK in the last 6 months, newest first. Each line links to its public source.
- 1 Nov 2026 Turned profitable · Turned profitable in FY2025: €192k net profit after a €2.0M loss registeruz.sk
About MagnaPharm SK
MagnaPharm SK provides pharmaceutical import, local distribution, marketing and professional support, and assistance with regulatory obligations.
The company serves pharmaceutical manufacturers and customers. Its registered headquarters are in Bratislava, Slovakia, and it was founded in 2005.
Product: Pharmaceutical import, local distribution, marketing and professional support, and regulatory services.
Financials
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | €50.5M | €5.0M | €3.6M | €1.8M | €1.4M |
| Growth | +902% | +40% | +103% | +31% | — |
| EBITDA | €363k | −€1.9M | −€2.2M | −€1.5M | −€871k |
| Operating profit | €244k | −€2.0M | −€2.2M | −€1.5M | −€873k |
| Net profit | €192k | −€2.0M | −€2.2M | −€1.5M | −€876k |
| Net margin | 0.4% | −39.9% | −61.6% | −82.5% | −64.9% |
| Personnel costs | €1.8M | €1.6M | €1.6M | €1.4M | €887k |
| Total assets | €20.1M | €3.0M | €2.5M | €2.0M | €1.9M |
| Cash | €0 | €0 | €29k | €507k | €338k |
| Liabilities | €19.7M | €2.9M | €3.3M | €693k | €1.6M |
| Equity | €303k | €111k | −€876k | €1.3M | €305k |
As filed with RÚZ (Slovak register of financial statements). Each year links to its statement.
Jobs at MagnaPharm SK
Leadership
- Karol Michalák · Konateľ (Managing director)Source: business register
- Marco Angelo Vinci · Konateľ (Managing director)Source: business register
- Miroslav Karas · Konateľ (Managing director)Source: business register
More biotech & pharma companies
MediXbank, n.o.
Nonprofit biomedical research and biobanking for researchers and healthcare professionalsNew on EvolcMGP
Distributes radiopharmaceuticals, contrast agents and radiation sources to healthcare, research and industry in Czechia and SlovakiaNew on EvolcMIKROCHEM
Pharmaceutical and chemical manufacturing and R&D services for pharmaceutical and chemical companiesMINITÜB SLOVAKIA
Assisted reproduction systems for animal insemination and embryo transfer, also used in human fertility treatmentProfitableMultiplexDX
Cancer diagnostics, molecular testing, and research services for healthcare and life-science organizationsGrowingNovo Nordisk Slovakia
Pharmaceutical company in Slovakia presenting prescription medicines and careers; Bratislava-based subsidiary of a foreign groupProfitable
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AzureMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Marketing & advertising
- Meta PixelMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinitialization/configuration expression
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.